Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allovir Inc ALVR

Healthcare Biotechnology
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life... see more

Recent & Breaking News (NDAQ:ALVR)

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses to Contact the Firm

Accesswire March 4, 2024

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALVR

Accesswire March 4, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 4, 2024

Investors who lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class Action - ALVR

Accesswire March 4, 2024

AlloVir, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire March 4, 2024

Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire March 4, 2024

UPCOMING ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 4, 2024

Levi & Korsinsky Reminds AlloVir, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

Accesswire March 3, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

PR Newswire March 3, 2024

Class Action Filed Against AlloVir, Inc. (ALVR) - March 19, 2024 Deadline to Join - Contact Levi & Korsinsky

Accesswire March 3, 2024

AlloVir Deadline Reminder

Newsfile March 3, 2024

UPCOMING ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 3, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR

Newsfile March 2, 2024

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire March 1, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

Accesswire March 1, 2024

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 1, 2024

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALVR

Accesswire March 1, 2024

Shareholders that lost money on AlloVir, Inc. (ALVR) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire March 1, 2024

AlloVir, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

Accesswire March 1, 2024

UPCOMING ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 1, 2024